753023-57-3

Usage

Uses

Used in Pharmaceutical Industry:
Carbamic acid, [1-(2-hydroxyethyl)cyclopropyl]-, 1,1-dimethylethyl ester (9CI) is used as a key intermediate in the synthesis of various drugs and medications. Its unique chemical structure allows it to be incorporated into the development of new pharmaceutical compounds, potentially leading to the discovery of novel therapeutic agents.
Used in Agricultural Processes:
Although not explicitly mentioned in the provided materials, the potential applications of Carbamic acid, [1-(2-hydroxyethyl)cyclopropyl]-, 1,1-dimethylethyl ester (9CI) in agricultural processes could include its use as a component in the development of new pesticides, herbicides, or other agrochemicals. Its unique properties may contribute to the creation of more effective and environmentally friendly agricultural products.
Used in Industrial Processes:
Similarly, the potential applications of Carbamic acid, [1-(2-hydroxyethyl)cyclopropyl]-, 1,1-dimethylethyl ester (9CI) in industrial processes could involve its use in the development of new materials, coatings, or other industrial chemicals. Its unique chemical structure may provide advantages in terms of performance, durability, or environmental impact when incorporated into industrial products.

Upstream product

• 753023-56-2 2-(1-Amino-cyclopropyl)-ethanol hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 388095-22-5 1-[2-(benzyloxy)ethyl]cyclopropan-1-amine 

Downstream Products

• 497861-78-6 tert-butyl N-[1-(2-oxoethyl)cyclopropyl]carbamate 

Relevant academic research and scientific papers

Organocatalytic conjugate addition of cyclopropylacetaldehyde derivatives to nitro olefins: En route to β- and γ-amino acids

Cyclopropane-containing amino acids are important pharmaceuticals and biologically active compounds. A new organocatalytic asymmetric Michael reaction has been developed. This allows the one-step introduction of the cyclopropane ring, as well as two different nitrogen-containing functional groups (tert-butoxycarbonylamino and nitro) into the target compounds. All the products were isolated in good yields with moderate to excellent enantio- and diastereoselectivities.

PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND

There are provided compounds having a superior PHD2 inhibitory effect that are represented by general formula (I'): (in the above-mentioned general formula (I'), W, Y, R2, R3, R4, and Y4 are as described hereinabove), or pharmaceutically acceptable salts thereof.

ISOXAZOLE β-LACTAMASE INHIBITORS

β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.

1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS

β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.

Substituted 8'-pyridinyl-dihydrospiro-(cycloalkyl)-pyrimido(1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro-(cycloalkyl)-pyrimido(1,2-a)pyrimidin-6-one derivatives and their use against neurodegenerative diseases

The invention relates to a dihydrospiro-[cycloalkyl]-pyrimidone derivative represented by formula (I) or a salt thereof: wherein:X represents two hydrogen atoms, a sulfur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom;Y represen